Table 1. Background Characteristics of Study Subjects.
Subject Groups | |||||
HIV Negative | All HIV-infected | Off Rx | Rx Viremic | Rx VL<500 | |
Subject Number | 10 | 40 | 17 | 12 | 11 |
Male | 10 | 38 | 15 | 12 | 11 |
Age, mean +/− SD | 47.5+/−6.3 | 45+/−5.0 | 42.5+/−5.7 | 46.3+/−4.8 | 47.5+/−7.7 |
Blood T cells, Median (IQR) | |||||
CD4+ cells/µl | 909 (609–919) | 251 (179–354) | 282 (236–442) | 211 (139–250) | 256 (172–576) |
CD8+ cells/ul | 406 (338–513) | 962 (704–1149) | 900 (750–1033) | 1018 (611–1268) | 1069 (789–1132) |
CD4:CD8 ratio | 1.85 (1.48–2.26) | 0.29 (0.18–0.46) | 0.36 (0.29–0.51) | 0.16 (0.14–0.25) | 0.39 (0.21–0.54) |
HIV RNA, log10 copies/ml, Median (IQR): | |||||
Plasma HIV RNA | NA | 4.05 (1.83–4.88) | 4.41 (4.00–4.89) | 4.72 (3.71–5.25) | 1.28 (1.28–1.76) |
CSF HIV RNA | NA | 3.02 (1.28–3.60) | 3.38 (3.07–4.55) | 2.88 (1.61–4.28) | 1.28 (1.28–1.28) |
CSF WBCs, Median (IQR): | |||||
Cells per ul | 1 (0.0–3.0) | 3 (1.0–8.0) | 5 (2.0–11.0) | 2.5 (1.0–9.5) | 1 (0.0–3.0) |
SD = standard deviation.
IQR = interquartile range.
NA = Not applicable.